Comparison of local tumor control in patients with HCC treated with SBRT or TACE: a propensity score analysis

BMC Cancer

Nicolas Glaser¹  Dominik Bettinger¹  Nico Buettner¹  Michael Schultheiss¹  Robert Thimme¹  Sophie Lange¹  Simon Kirste²  Eleni Gkika²  Anca-Ligia Grosu²  Thomas B. Brunner²  Ursula Nestle²  Lars Maruschke³ 

[1] Department of Medicine II, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg;Department of Radiation Oncology, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg;Department of Radiology, Medical Center University Freiburg, Faculty of Medicine, University of Freiburg;

关键词: Hepatocellular carcinoma;    Transarterial chemoembolization;    Stereotactic body radiation therapy;    Propensity score analysis;    Overall survival;   

DOI  :  10.1186/s12885-018-4696-8

来源: DOAJ

【 摘 要 】

Abstract Background As stereotactic body radiation therapy (SBRT) has shown to be effective and safe in patients with hepatocellular carcinoma (HCC), the aim of our propensity score matched analysis was to evaluate the efficacy of SBRT in comparison to transarterial chemoembolization (TACE) in intermediate and advanced HCC. Methods Patients treated with TACE (n = 367) and patients allocated to SBRT (n = 35) were enrolled in this study. Propensity score matching was performed to adjust for differences in baseline and tumor characteristics of TACE and SBRT patients. Local tumor control (LC) 1 year after treatment, overall survival (OS) and 1-year mortality were assessed. Results Patients treated with SBRT have received more prior HCC treatments compared to TACE patients. The LC 1 year after treatment in the unmatched cohort was 74.4% for TACE patients compared to 84.8% in the SBRT group. Patients treated with TACE showed significantly improved OS (17.0 months vs. 9.0 months, p = 0.016). After propensity score matching, the LC in the TACE (n = 70) and SBRT (n = 35) group was comparable (82.9% vs. 84.8%, p = 0.805) and OS did not differ significantly in both groups. Conclusions SBRT after prior HCC therapy in selected patients shows comparable LC at 1 year, OS and 1-year mortality compared to patients treated with TACE.

【 授权许可】

Unknown